Instil Bio enters collaboration for ITIL-306 preclinical manufacturing feasibility studies

Instil Bio, Inc.

Agreement with collaborator for preclinical manufacturing feasibility studies on ITIL-306 program.
Aims to enroll patients in investigator-initiated clinical trials (IITs).
No guidance provided on timing of data readout for ITIL-306 or IIT studies.
Forward-looking statements subject to risks including manufacturing and enrollment uncertainties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.